Hot on the tail of Galapagos’ successful public offering, Gent-based biotech Argenx is following suit! The biotech company, which is developing antibody-based therapies for cancer and autoimmune diseases, is offering $300 millions ADSs. This is the same amount offered by Galapagos, just last week. Belgian biotech is on a roll! All we can ask is; who’s next?
17 September 2018 – Read the full press release here.
Argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced an underwritten U.S. public offering of American Depositary Shares (ADSs) and an offering of ADSs in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering). argenx aims to offer and sell, subject to market and other conditions, ADSs for approximately $300 million. Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of €0.10 per share. All of the ADSs in the proposed Offering are to be sold by argenx. The final price per ADS in the Offering will be determined following the accelerated bookbuilding process.
